secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001558370-22-016263
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure discontinues NC318 program; Q3 net loss $18.9M, cash runway extended to mid‑2025
--------------------------------------------------------------------------------

- Discontinued NC318 development after no responses in Phase 2 monotherapy; continuing Yale combo trial.
- Cash, cash equivalents and marketable securities at Sept 30, 2022: $169.2M, down from $219.6M at Dec 31, 2021.
- Q3 2022 net loss $18.9M vs $17.9M in Q3 2021; R&D expense flat at $13.5M, G&A up to $5.7M.
- Cash runway extended by 15 months; now expected to fund operations into mid‑2025.
- Advancing NC410 Phase 1b/2 combo trial, NC525 Phase 1 expected Q1 2023, and NC762 expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837022016263/0001558370-22-016263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837022016263/nxtc-20221103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer